Charlotte Bevan

List of Publications by Year
in descending order

80 papers	3,896 citations	117571 34 h-index	128225 60 g-index
100 all docs	100 docs citations	100 times ranked	5397 citing authors

#	Article	IF	Citations
1	Targeting androgen signaling in ILC2s protects from IL-33â€“driven lung inflammation, independently of KLRG1. Journal of Allergy and Clinical Immunology, 2022, 149, 237-251.e12.	1.5	23
2	MicroRNAs as biomarkers for prostate cancer prognosis: a systematic review and a systematic reanalysis of public data. British Journal of Cancer, 2022, 126, 502-513.	2.9	28
3	Crosstalk between Long Non Coding RNAs, microRNAs and DNA Damage Repair in Prostate Cancer: New Therapeutic Opportunities?. Cancers, 2022, 14, 755.	1.7	12
4	A non-coding RNA balancing act: miR-346-induced DNA damage is limited by the long non-coding RNA NORAD in prostate cancer. Molecular Cancer, 2022, 21, 82.	7.9	6
5	Transcription associated cyclin-dependent kinases as therapeutic targets for prostate cancer. Oncogene, 2022, 41, 3303-3315.	2.6	16
6	Eighty Years of Targeting Androgen Receptor Activity in Prostate Cancer: The Fight Goes on. Cancers, 2021, 13, 509.	1.7	29
7	Follicleâ€stimulating hormone promotes growth of human prostate cancer cell lineâ€derived tumor xenografts. FASEB Journal, 2021, 35, e21464.	0.2	9
8	A Suite of Activity-Based Probes To Dissect the KLK Activome in Drug-Resistant Prostate Cancer. Journal of the American Chemical Society, 2021, 143, 8911-8924.	6.6	14
9	Single-molecule amplification-free multiplexed detection of circulating microRNA cancer biomarkers from serum. Nature Communications, 2021, 12, 3515.	5.8	107
10	Roles of steroid receptors in the lung and COVID-19. Essays in Biochemistry, 2021, 65, 1025-1038.	2.1	11
11	The antiandrogen enzalutamide downregulates TMPRSS2 and reduces cellular entry of SARS-CoV-2 in human lung cells. Nature Communications, 2021, 12, 4068.	5.8	57
12	Breaking down walls in prostate cancer with the MURAL collection of patient-derived xenografts. Nature Communications, 2021, 12, 5504.	5.8	0
13	Cytoreductive treatment strategies for de novo metastatic prostate cancer. Nature Reviews Clinical Oncology, 2020, 17, 168-182.	12.5	36
14	High fat diet causes distinct aberrations in the testicular proteome. International Journal of Obesity, 2020, 44, 1958-1969.	1.6	17
15	Identification of transcription factor co-regulators that drive prostate cancer progression. Scientific Reports, 2020, 10, 20332.	1.6	19
16	Coordinated AR and microRNA regulation in prostate cancer. Asian Journal of Urology, 2020, 7, 233-250.	0.5	14
17	Building a synthetic mechanosensitive signaling pathway in compartmentalized artificial cells. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 16711-16716.	3.3	98
18	Liver X Receptors and Male (In)fertility. International Journal of Molecular Sciences, 2019, 20, 5379.	1.8	10

#	Article	IF	Citations
19	Androgen receptor-modulatory microRNAs provide insight into therapy resistance and therapeutic targets in advanced prostate cancer. Oncogene, 2019, 38, 5700-5724.	2.6	59
20	MiR-1271-5p: An AR-modulatory microRNA with a distinct role in prostate cancer progression, through SND1 and MORF4L1 interaction.. Journal of Clinical Oncology, 2019, 37, e16562-e16562.	0.8	0
21	Role of Androgen Receptor Variants in Prostate Cancer: Report from the 2017 Mission Androgen Receptor Variants Meeting. European Urology, 2018, 73, 715-723.	0.9	105
22	Light-triggered enzymatic reactions in nested vesicle reactors. Nature Communications, 2018, 9, 1093.	5.8	125
23	Midazolam and Dexmedetomidine Affect Neuroglioma and Lung Carcinoma Cell Biology <i>In Vitro</i> and <i>In Vivo</i>. Anesthesiology, 2018, 129, 1000-1014.	1.3	65
24	Consensus Statement on Circulating Biomarkers for Advanced Prostate Cancer. European Urology Oncology, 2018, 1, 151-159.	2.6	28
25	Novel Trifluoromethylated Enobosarm Analogues with Potent Antiandrogenic Activity <i>In Vitro</i> and Tissue Selectivity <i>In Vivo</i>. Molecular Cancer Therapeutics, 2018, 17, 1846-1858.	1.9	7
26	Consensus statement on circulating biomarkers for advanced prostate cancer.. Journal of Clinical Oncology, 2018, 36, 299-299.	0.8	1
27	A novel role for GSK3Î² as a modulator of Drosha microprocessor activity and MicroRNA biogenesis. Nucleic Acids Research, 2017, 45, gkw938.	6.5	17
28	The prohibitin-repressive interaction with E2F1 is rapidly inhibited by androgen signalling in prostate cancer cells. Oncogenesis, 2017, 6, e333-e333.	2.1	18
29	Lipid profiling of complex biological mixtures by liquid chromatography/mass spectrometry using a novel scanning quadrupole dataâ€independent acquisition strategy. Rapid Communications in Mass Spectrometry, 2017, 31, 1599-1606.	0.7	18
30	Cell-lineage specificity and role of AP-1 in the prostate fibroblast androgen receptor cistrome. Molecular and Cellular Endocrinology, 2017, 439, 261-272.	1.6	27
31	A circulating miRNA signature to help prognosticate at prostate cancer diagnosis.. Journal of Clinical Oncology, 2017, 35, 108-108.	0.8	1
32	A signature of miRNAs in the blood to help prognosticate prostate cancer at the time of diagnosis.. Journal of Clinical Oncology, 2017, 35, e16558-e16558.	0.8	0
33	Circulating Nucleic Acids as Prostate Cancer Biomarkers. , 2016, , 557-585.		0
34	Amplification-Free Detection of Circulating microRNA Biomarkers from Body Fluids Based on Fluorogenic Oligonucleotide-Templated Reaction between Engineered Peptide Nucleic Acid Probes: Application to Prostate Cancer Diagnosis. Analytical Chemistry, 2016, 88, 8091-8098.	3.2	50
35	WOMEN IN CANCER THEMATIC REVIEW: New roles for nuclear receptors in prostate cancer. Endocrine-Related Cancer, 2016, 23, T85-T108.	1.6	23
36	In Vivo Imaging of Nuclear Receptor Transcriptional Activity. Methods in Molecular Biology, 2016, 1443, 203-217.	0.4	3

#	Article	IF	Citations
37	Advances in genetics: widening our understanding of prostate cancer. F1000Research, 2016, 5, 1512.	0.8	2
38	WOMEN IN CANCER PROFILE: A gender agenda?. Endocrine-Related Cancer, 2016, 23, P5-P8.	1.6	1
39	Antiandrogens Act as Selective Androgen Receptor Modulators at the Proteome Level in Prostate Cancer Cells*. Molecular and Cellular Proteomics, 2015, 14, 1201-1216.	2.5	10
40	The coâ€chaperone p23 promotes prostate cancer motility and metastasis. Molecular Oncology, 2015, 9, 295-308.	2.1	27
41	Revising the role of the androgen receptor in breast cancer. Journal of Molecular Endocrinology, 2014, 52, R257-R265.	1.1	72
42	Prostate cancer cell malignancy via modulation of HIF-1Î± pathway with isoflurane and propofol alone and in combination. British Journal of Cancer, 2014, 111, 1338-1349.	2.9	203
43	Interplay between steroid signalling and microRNAs: implications for hormone-dependent cancers. Endocrine-Related Cancer, 2014, 21, R409-R429.	1.6	31
44	Phosphorylation of activating transcription factor-2 (ATF-2) within the activation domain is a key determinant of sensitivity to tamoxifen in breast cancer. Breast Cancer Research and Treatment, 2014, 147, 295-309.	1.1	21
45	Engineered repressors are potent inhibitors of androgen receptor activity. Oncotarget, 2014, 5, 959-969.	0.8	6
46	Circulating microRNAs as potential new biomarkers for prostate cancer. British Journal of Cancer, 2013, 108, 1925-1930.	2.9	130
47	Mini-review: Foldosome regulation of androgen receptor action in prostate cancer. Molecular and Cellular Endocrinology, 2013, 369, 52-62.	1.6	52
48	Circulating nucleic acids as biomarkers of prostate cancer. Biomarkers in Medicine, 2013, 7, 867-877.	0.6	20
49	Circulating peripheral blood mononuclear cells exhibit altered miRNA expression patterns in pancreatic cancer. Expert Review of Molecular Diagnostics, 2013, 13, 425-430.	1.5	20
50	Visualising Androgen Receptor Activity in Male and Female Mice. PLoS ONE, 2013, 8, e71694.	1.1	80
51	Androgen-regulated processing of the oncomir MiR-27a, which targets Prohibitin in prostate cancer. Human Molecular Genetics, 2012, 21, 3112-3127.	1.4	127
52	Role of the HSP90-Associated Cochaperone p23 in Enhancing Activity of the Androgen Receptor and Significance for Prostate Cancer. Molecular Endocrinology, 2012, 26, 1694-1706.	3.7	35
53	Reducing prohibitin increases histone acetylation, and promotes androgen independence in prostate tumours by increasing androgen receptor activation by adrenal androgens. Oncogene, 2012, 31, 4588-4598.	2.6	20
54	Allosteric Conversation in the Androgen Receptor Ligand-Binding Domain Surfaces. Molecular Endocrinology, 2012, 26, 1078-1090.	3.7	58

#	Article	IF	Citations
55	Metabolic signatures of malignant progression in prostate epithelial cells. International Journal of Biochemistry and Cell Biology, 2011, 43, 1002-1009.	1.2	47
56	FUS/TLS Is a Novel Mediator of Androgen-Dependent Cell-Cycle Progression and Prostate Cancer Growth. Cancer Research, 2011, 71, 914-924.	0.4	59
57	Repression of Androgen Receptor Activity by HEYL, a Third Member of the Hairy/Enhancer-of-split-related Family of Notch Effectors. Journal of Biological Chemistry, 2011, 286, 17796-17808.	1.6	37
58	Androgen Receptor Signalling in Prostate Cancer: The Functional Consequences of Acetylation. Journal of Biomedicine and Biotechnology, 2011, 2011, 1-7.	3.0	30
59	Interaction between AR signalling and CRKL bypasses casodex inhibition in prostate cancer. Cellular Signalling, 2010, 22, 1874-1881.	1.7	6
60	HEY1 Leu94Met gene polymorphism dramatically modifies its biological functions. Oncogene, 2010, 29, 411-420.	2.6	24
61	The Role of Androgen Receptor Mutations in Prostate Cancer Progression. Current Genomics, 2009, 10, 18-25.	0.7	147
62	Manipulating prohibitin levels provides evidence for an in vivo role in androgen regulation of prostate tumours. Endocrine-Related Cancer, 2009, 16, 1157-1169.	1.6	50
63	Mechanisms of androgen receptor activation in advanced prostate cancer: differential co-activator recruitment and gene expression. Oncogene, 2008, 27, 2941-2950.	2.6	73
64	Notch Signaling: A Potential Therapeutic Target in Prostate Cancer. Current Cancer Drug Targets, 2008, 8, 566-580.	0.8	44
65	Proteomic analysis of proteins regulated by TRPS1 transcription factor in DU145 prostate cancer cells. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2007, 1774, 575-582.	1.1	12
66	Prohibitin, a protein downregulated by androgens, represses androgen receptor activity. Oncogene, 2007, 26, 1757-1768.	2.6	74
67	Impact of Analytical Bias in Metabonomic Studies of Human Blood Serum and Plasma. Analytical Chemistry, 2006, 78, 4307-4318.	3.2	226
68	Mechanisms of androgen receptor repression in prostate cancer. Biochemical Society Transactions, 2006, 34, 1124-1127.	1.6	17
69	Hey1, a Mediator of Notch Signaling, Is an Androgen Receptor Corepressor. Molecular and Cellular Biology, 2005, 25, 1425-1436.	1.1	120
70	Androgen receptor in prostate cancer: cause or cure?. Trends in Endocrinology and Metabolism, 2005, 16, 395-397.	3.1	8
71	Androgen Receptor Is Targeted to Distinct Subcellular Compartments in Response to Different Therapeutic Antiandrogens. Clinical Cancer Research, 2004, 10, 7392-7401.	3.2	31
72	Mechanisms of androgen receptor signalling via steroid receptor coactivator-1 in prostate.. Endocrine-Related Cancer, 2004, 11, 117-130.	1.6	71

#	Article	IF	Citations
73	Androgens target prohibitin to regulate proliferation of prostate cancer cells. Oncogene, 2004, 23, 2996-3004.	2.6	96
74	Characterization of the Two Coactivator-interacting Surfaces of the Androgen Receptor and Their Relative Role in Transcriptional Control*. Journal of Biological Chemistry, 2002, 277, 49230-49237.	1.6	71
75	Analysis of the Steroid Receptor Coactivator 1 (SRC1)-CREB Binding Protein Interaction Interface and Its Importance for the Function of SRC1. Molecular and Cellular Biology, 2001, 21, 39-50.	1.1	98
76	The Role of Coactivators in Steroid Hormone Action. Experimental Cell Research, 1999, 253, 349-356.	1.2	57
77	The AF1 and AF2 Domains of the Androgen Receptor Interact with Distinct Regions of SRC1. Molecular and Cellular Biology, 1999, 19, 8383-8392.	1.1	371
78	Phenotypic diversity in siblings with partial androgen insensitivity syndrome. Archives of Disease in Childhood, 1997, 76, 529-531.	1.0	60
79	Wide variation in androgen receptor dysfunction in complete androgen insensitivity syndrome. Journal of Steroid Biochemistry and Molecular Biology, 1997, 61, 19-26.	1.2	30
80	Functional Analysis of Six Androgen Receptor Mutations Identified in Patients with Partial Androgen Insensitivity Syndrome. Human Molecular Genetics, 1996, 5, 265-273.	1.4	69